|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 5,934.00 JPY | -1.02% |
|
-2.34% | -25.29% |
| 04-13 | Cosmos Pharmaceutical's Nine-Month Profit Rises 1.8% | MT |
| 04-13 | Cosmos Pharmaceutical Corporation Provides Consolidated Earnings Guidance for the Full Year of Fiscal Year Ending May 31, 2026 | CI |
Company Valuation: COSMOS Pharmaceutical Corporation
Data adjusted to current consolidation scope
| Fiscal Period: May | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|---|---|---|
| Market Cap 1 | 603,094 | 483,107 | 525,081 | 502,890 | 700,001 | 470,313 | - | - |
| Change | - | -19.9% | 8.69% | -4.23% | 39.2% | -32.81% | - | - |
| Enterprise Value (EV) 1 | 553,560 | 450,132 | 497,354 | 477,918 | 692,920 | 452,725 | 439,453 | 431,812 |
| Change | - | -18.68% | 10.49% | -3.91% | 44.99% | -34.66% | -2.93% | -1.74% |
| P/E | 22.2x | 20.9x | 22.1x | 20.6x | 22.6x | 14.8x | 14.2x | 13.4x |
| PBR | 3.54x | 2.54x | 2.49x | 2.17x | 2.72x | 1.66x | 1.51x | 1.38x |
| PEG | - | -1.4x | 7.98x | 7.61x | 0.8x | 5.21x | 3.71x | 2.35x |
| Capitalization / Revenue | 0.83x | 0.64x | 0.63x | 0.52x | 0.69x | 0.43x | 0.4x | 0.37x |
| EV / Revenue | 0.76x | 0.6x | 0.6x | 0.5x | 0.69x | 0.41x | 0.37x | 0.34x |
| EV / EBITDA | 11.8x | 10x | 10.5x | 9.29x | 11.1x | 6.83x | 6.26x | 5.8x |
| EV / EBIT | 16.7x | 15.1x | 16.5x | 15.2x | 17.1x | 10.8x | 10x | 9.35x |
| EV / FCF | 65.2x | -39.1x | 93.5x | -222x | -807x | 104x | 66.2x | 54.1x |
| FCF Yield | 1.53% | -2.56% | 1.07% | -0.45% | -0.12% | 0.96% | 1.51% | 1.85% |
| Dividend per Share 2 | 35 | 40 | 50 | 60 | 70 | 76.07 | 82.21 | 88.7 |
| Rate of return | 0.46% | 0.66% | 0.75% | 0.95% | 0.79% | 1.28% | 1.39% | 1.49% |
| EPS 2 | 342.9 | 292.4 | 300.5 | 308.6 | 390.9 | 402 | 417.4 | 441.2 |
| Distribution rate | 10.2% | 13.7% | 16.6% | 19.4% | 17.9% | 18.9% | 19.7% | 20.1% |
| Net sales 1 | 726,424 | 755,414 | 827,697 | 964,989 | 1,011,390 | 1,094,270 | 1,176,942 | 1,255,881 |
| EBITDA 1 | 46,932 | 44,906 | 47,496 | 51,425 | 62,633 | 66,263 | 70,212 | 74,503 |
| EBIT 1 | 33,147 | 29,796 | 30,128 | 31,501 | 40,404 | 41,966 | 43,776 | 46,181 |
| Net income 1 | 27,156 | 23,155 | 23,797 | 24,454 | 30,978 | 31,858 | 33,082 | 34,973 |
| Net Debt 1 | -49,534 | -32,975 | -27,727 | -24,972 | -7,081 | -17,588 | -30,859 | -38,501 |
| Reference price 2 | 7,615.00 | 6,100.00 | 6,630.00 | 6,345.00 | 8,832.00 | 5,934.00 | 5,934.00 | 5,934.00 |
| Nbr of stocks (in thousands) | 79,198 | 79,198 | 79,198 | 79,258 | 79,257 | 79,257 | - | - |
| Announcement Date | 12/07/21 | 11/07/22 | 10/07/23 | 12/07/24 | 11/07/25 | - | - | - |
1JPY in Million2JPY
Estimates
P/E, Detailed evolution
| P/E (Y) | EV / Sales (Y) | EV / EBITDA (Y) | Dividend Yield (Y) | Capi.($) | ||
|---|---|---|---|---|---|---|
 | 14.91x | 0.42x | 6.91x | 1.27% | 2.95B | |
| 20.04x | 0.32x | 5.29x | 2.48% | 5.54B | |
| 17.19x | 0.47x | 6.75x | 1.16% | 3.52B | |
| 13.98x | 0.44x | 5.72x | 3.5% | 2.75B | |
| 18.93x | 0.73x | 10.22x | 1.59% | 2.12B | |
| 13.62x | 0.41x | 3.92x | 3.65% | 1.33B | |
| 16.72x | 0.49x | 6.09x | 4.32% | 355M | |
| Average | 16.49x | 0.47x | 6.41x | 2.57% | 2.65B | |
| Weighted average by Cap. | 17.14x | 0.44x | 6.37x | 2.21% |
Y-o-Y evolution of P/E
Historical PBR trend
Evolution Enterprise Value / Sales
Change in Enterprise Value/EBITDA
Year-on-year evolution of the Yield
- Stock Market
- Stocks
- 3349 Stock
- Valuation COSMOS Pharmaceutical Corporation
Select your edition
All financial news and data tailored to specific country editions
